BRAF and non-small cell lung carcinoma: The sensitivity of dabrafenib, a selective inhibitor of mutated forms of BRAF kinase for BRAF-mutated melanoma, thyroid cancer, and non-small-cell lung cancer, was found to be positively associated with PPARGC1A (correlation coefficient = 0.448, p < 0.001) and PPARGC1B (correlation coefficient = 0.377, p = 0.003).